Should the health-care personnel treating a patient infected with a multidrug-resistant strain undergo carrier screening? If yes, when should the tests be performed: on a regular basis in all staff or only in case of exposure?
Is it advisable to perform screening tests for certain drug-resistant pathogens in patients admitted to a hospital? If so, who should be tested? Should we perform such screening tests in patients with a history of documented drug-resistant bacterial strain infection?
What are the alternative treatments in patients with multidrug-resistant bacterial strain infections? Could such treatments (eg, phage therapy) offer a chance for cure in such patients?
Why has the emergence of New Delhi Metallo-beta-lactamase-1 (NDM-1) resistance caused concern of disease control authorities?
What are the key differences between microbial floras in the hospital and community settings?
Is the virulence of community-acquired and hospital drug-resistant bacterial strains (eg, methicillin-resistant Staphylococcus aureus) the same? Are drug-resistant strain infections limited to patients with risk factors or can they also affect healthy persons with no risk factors?
What is the role of fecal microbiota transplantation (FMT) in the treatment of Clostridium difficile infection?
What patients are at the highest risk of developing Clostridium difficile infection?
Can multidrug-resistant bacterial strains become so widespread that even minor infections could develop into life-threatening conditions, as it used to be in the pre-antibiotic era?
What are the causes of antimicrobial drug resistance and can it be prevented? If not, how can we reduce the risk of development of local (eg, in hospitals) or global drug resistance?
English
Polski
Español
українська